<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Inherited ichthyosis: Overview of management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Inherited ichthyosis: Overview of management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Inherited ichthyosis: Overview of management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amy S Paller, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sneha Butala, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer L Hand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1868943467">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ichthyoses are a heterogeneous group of hereditary disorders of keratinization of varying severity characterized by hyperkeratosis and scaling, often associated with underlying inflammation. They are caused by pathogenic variants in genes encoding epidermal structural proteins and enzymes that affect synthesis or metabolism of proteins and lipids involved in maintaining and regulating the stratum corneum and the epidermal barrier function. The defective skin barrier results in increased transepidermal water loss, compensatory epidermal hyperplasia and/or epidermal retention hyperkeratosis, and, in most patients, some degree of inflammation.
        </p>
        <p>
         There are no specific therapies for ichthyosis known to be useful in all patients. Treatment is individualized according to ichthyosis type and personal preference. Skin care measures and use of topical or systemic medications aimed at reducing hyperkeratosis and scaling and hydrating and softening the skin can provide symptomatic relief in most patients. However, more recent understanding of the pathogenesis of ichthyosis subtypes is leading to more targeted treatment with anti-inflammatory biologics, small molecule inhibitors, and gene replacement therapy.
        </p>
        <p>
         This topic will discuss the approach to the management of patients with ichthyosis. The pathogenesis, clinical presentation, and diagnosis of specific types of ichthyosis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">
          "Overview and classification of the inherited ichthyoses"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15471.html" rel="external">
          "Ichthyosis vulgaris"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15472.html" rel="external">
          "X-linked ichthyosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/112583.html" rel="external">
          "Autosomal recessive congenital ichthyoses"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97333.html" rel="external">
          "Keratinopathic ichthyoses"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110147.html" rel="external">
          "Palmoplantar keratoderma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15474.html" rel="external">
          "Netherton syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2666648382">
         <span class="h1">
          GENERAL CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no curative therapies for ichthyosis. Treatment is largely symptomatic, aimed at reducing skin dryness and scaling, limiting excess transepidermal water loss, hydrating and softening the stratum corneum, promoting desquamation of scales, and controlling inflammation and pruritus [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'General measures'
         </a>
         below.)
        </p>
        <p>
         Decision making about the choice and aggressiveness of therapy depends on the age of the patient, morphology, distribution, severity of disease, whether the disorder is limited to the skin (nonsyndromic ichthyosis) or involves internal organs and systems as well (syndromic ichthyosis), and safety of long-term therapy  (
         <a class="graphic graphic_table graphicRef90504 graphicRef90509" href="/z/d/graphic/90504.html" rel="external">
          table 1A-B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">
          "Overview and classification of the inherited ichthyoses", section on 'Nonsyndromic inherited ichthyoses'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">
          "Overview and classification of the inherited ichthyoses", section on 'Syndromic ichthyoses'
         </a>
         .)
        </p>
        <p>
         Because ichthyoses and other disorders of differentiation are chronic, patients require long-term, comprehensive care. For patients with severe or syndromic forms of ichthyosis, early consultation with a multidisciplinary team of specialists (including dermatology, genetics, neonatology, ophthalmology, otolaryngology, orthopedic and plastic surgery, occupational and physical therapy, nutrition, and social services) is essential. Psychiatric and mental health support for patients and their families/caregivers is also of utmost importance and should address issues affecting coping strategies and quality of life [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1802106152">
         <span class="h1">
          GENERAL MEASURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         General skin care measures, including frequent tub soaks or showers, environment humidification, exfoliation, and liberal use of emollients, are the foundation of ichthyosis management [
         <a href="#rid1">
          1,3
         </a>
         ]. Patients and families/caregivers can be referred to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=128456" target="_blank">
          Foundation for Ichthyosis and Related Skin Types (FIRST)
         </a>
         website for guidance and tips from experts, including information about skin care products [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H444504974">
         <span class="h2">
          Bathing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of patients with congenital forms of ichthyosis find prolonged, daily or twice-daily baths (at least 30 minutes of soaking) to be extremely valuable for softening scales before exfoliation. Bath additives (sodium chloride,
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , sodium hypochlorite,
         <a class="drug drug_general" data-topicid="9277" href="/z/d/drug information/9277.html" rel="external">
          acetic acid
         </a>
         /vinegar) are helpful to reduce odor (thought to result from bacterial overgrowth in the excessive scale), pruritus, and to help with exfoliation  (
         <a class="graphic graphic_table graphicRef134098" href="/z/d/graphic/134098.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4-8
         </a>
         ]. Patients are encouraged to try different additives, as benefit and tolerance of products varies on an individual basis. Superfatted soap or soapless "synthetic detergents" may be better tolerated than regular soaps or body washes. Oils can also be added to baths, but they make bathtubs slippery, and care must be taken to avoid falls.
        </p>
        <p>
         Anecdotal patient experiences support the use of bathtubs producing microbubbles and portable devices using micro/nanobubble technology to improve skin hydration and exfoliation, as well as to decrease irritation, bacterial load, and odor. However, no studies have tested their benefit for ichthyoses.
        </p>
        <p class="headingAnchor" id="H3132195785">
         <span class="h2">
          Exfoliating
         </span>
         <span class="headingEndMark">
          —
         </span>
         Removal of scales while bathing, particularly in patients with lamellar ichthyosis, recessive X-linked ichthyosis, and epidermolytic ichthyosis, can be accomplished by gently rubbing on the affected areas with a loofah sponge, bathing glove or mitt, or pumice bars or stones. Pumice stones with smaller pores are gentler and may be best for sensitive areas, whereas those with larger pores are suitable for the hyperkeratotic skin of the hands and feet. Stones should be cleaned well after use using a bristled brush and can be boiled in hot water for five minutes to reduce the bacterial load on the surface. Drills and mechanical paring instruments can be helpful for exfoliating thicker scales on the hands and feet.
        </p>
        <p class="headingAnchor" id="H2602828977">
         <span class="h2">
          Moisturizing
         </span>
         <span class="headingEndMark">
          —
         </span>
         After bathing and exfoliating, a thick layer of moisturizer should immediately be applied to retain hydration and soften the skin. Adding a few ounces of a humectant, such as
         <a class="drug drug_general" data-topicid="8959" href="/z/d/drug information/8959.html" rel="external">
          glycerin
         </a>
         , can prolong moisturization [
         <a href="#rid9">
          9,10
         </a>
         ]. Moisturizers may also reduce inflammation and improve the barrier function. Application of petroleum jelly has been shown to increase expression of antimicrobial peptides and upregulate innate immunity genes through selective modulation of the proinflammatory T helper type 17 (Th17) and T helper type 22 (Th22) pathways [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         For most patients with ichthyosis, ointments, which have the highest oil-to-water ratio, are preferred. However, during hot, humid weather, occlusive moisturizers may worsen heat intolerance and favor the development of folliculitis or miliaria. If needed, less occlusive products (eg, creams or lotions) may be used. Because of the recognized increased risk of cutaneous infection with
         <em>
          Staphylococcus aureus
         </em>
         (including methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         [MRSA]) and fungi and demonstration of dysbiosis on ichthyotic skin [
         <a href="#rid12">
          12
         </a>
         ], patients should be reminded not to "double dip" into their moisturizer jars and potentially transfer bacteria into them. Items such as disposable spoons or popsicle sticks can be used to scoop out moisturizer from the containers [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Thick emollients (eg, petrolatum) can stain clothes and other fabrics. Either presoaking clothing with hydrogen peroxide-based stain removers or vinegar or adding one-fourth cup of vinegar to a standard laundry load can help remove stains and reduce odor.
        </p>
        <p class="headingAnchor" id="H2159255594">
         <span class="h2">
          Scalp care
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with skin, scalp scale and dryness are best managed by scale moisturization and removal. Scale can be softened with a variety of oils, ranging from
         <a class="drug drug_general" data-topicid="10213" href="/z/d/drug information/10213.html" rel="external">
          mineral oil
         </a>
         to coconut oil and other vegetable oils, prior to shampooing. Virgin coconut oil has been shown to be effective in reducing inflammation and transepidermal water loss in patients with atopic dermatitis and seems to have antibacterial properties against
         <em>
          S. aureus
         </em>
         [
         <a href="#rid13">
          13,14
         </a>
         ]. In contrast, olive oil has been associated with increased inflammation, and tea tree oil is a recognized sensitizer [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p>
         Wetting the scalp before application of oil can improve its effect. Use of a shower cap or plastic wrap both decreases mess and may increase penetration through its occlusion.
         <a class="drug drug_general" data-topicid="8458" href="/z/d/drug information/8458.html" rel="external">
          Fluocinolone
         </a>
         0.01% oil  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 3
         </a>
         ) can be substituted for unmedicated oil intermittently for patients who also experience scalp pruritus. The oil can be left on for an hour to overnight before shampooing. A shampoo containing a keratolytic agent (eg, alpha-hydroxy acids, beta-hydroxy acids, propylene glycol) can further help to loosen scales. After shampooing and use of conditioner if desired, scales can be further removed with a brush or comb.
        </p>
        <p class="headingAnchor" id="H1256400923">
         <span class="h2">
          Control of pruritus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pruritus is a major issue for patients with ichthyosis. Scratching, sleep disturbance, and loss of concentration result in poor quality of life [
         <a href="#rid18">
          18
         </a>
         ]. Measures that help reduce pruritus in patients with ichthyosis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Keeping the skin moist with regular, frequent use of emollients. Moisturizers containing oat milk or colloidal oatmeal may also be beneficial due to the anti-inflammatory properties of colloidal oatmeal extracts [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wearing looser clothing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimizing exposure to heat and humidity and applying cooling compresses to itchy areas.
        </p>
        <p>
        </p>
        <p>
         First-generation, sedating oral antihistamines (ie,
         <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">
          hydroxyzine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ) may be helpful for nighttime itching that disrupts sleep. Nonsedating antihistamines are generally ineffective. (See
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">
          "Pruritus: Therapies for localized pruritus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1033702004">
         <span class="h2">
          Prevention of overheating
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ineffective sweating and resultant heat intolerance with hyperthermia is an issue for many individuals with congenital ichthyosis. Thickened skin, keratin plugging of sweat glands, and abnormalities in eccrine system development may contribute to ineffective sweating.
        </p>
        <p>
         Measures to avoid overheating and reduce body temperature include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoiding exposure to high environmental temperatures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using caution in direct sunlight
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Staying hydrated with fluids
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recognizing signs of overheating (eg, facial flushing and reddened skin)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Being cognizant of when body temperature rises (eg, knowing when to stop during sports or exercise)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dousing the face or body with water or wearing a wet T-shirt
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using cooling bandanas, cool packs, or cooling vests
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Considering providing an education plan (eg, a 504 plan or Individualized Educational Plan [IEP] in the United States) for students to have access to a cool environment and water during physical education if needed
        </p>
        <p>
        </p>
        <p>
         Additional information on overheating and suggestions for keeping cool can be found online at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nfed.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2FyT8cU2O8GtHdX75aHgrsy4%3D&amp;TOPIC_ID=128456" target="_blank">
          National Foundation for Ectodermal Dysplasias
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=128456" target="_blank">
          Foundation for Ichthyosis and Related Skin Types (FIRST)
         </a>
         [
         <a href="#rid20">
          20,21
         </a>
         ]. FIRST also includes a list of cooling products with company contact information. Many individuals have experienced increased ability to sweat after puberty, perhaps related to increased eccrine and apocrine gland function. Some patients have reported improvement in sweating with the use of systemic retinoids [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4195003715">
         <span class="h1">
          TOPICAL KERATOLYTIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical keratolytic agents are first-line treatment for reducing scale in children and adults with ichthyosis. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=128456" target="_blank">
          Foundation for Ichthyosis and Related Skin Types (FIRST)
         </a>
         provides a product listing to patients with ichthyosis and their families/caregivers upon request. Alpha-hydroxy acids, beta-hydroxy acids,
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         preparations, and propylene glycol are most commonly used. The response of different types of ichthyosis to topical keratolytic agents is summarized in the table  (
         <a class="graphic graphic_table graphicRef134195" href="/z/d/graphic/134195.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha-hydroxy and beta-hydroxy acids
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glycolic acid and lactic acid are the most commonly used alpha-hydroxy acids [
         <a href="#rid7">
          7
         </a>
         ]. Glycolic acid at 5 to 10% concentrations is included in over-the-counter creams and lotions at a relatively low cost. Higher concentrations used in chemical peels for cosmetic purposes are not recommended for ichthyoses treatment [
         <a href="#rid7">
          7
         </a>
         ]. Lactic acid preparations have the added benefit of increasing ceramide production, which may improve the skin barrier [
         <a href="#rid24">
          24-26
         </a>
         ]. Concentrations ranging from 5 to 12% have been beneficial in treating ichthyosis [
         <a href="#rid27">
          27,28
         </a>
         ]. Stronger preparations can be found over the counter, but irritation limits use. Examples of lactic acid preparations include over-the-counter AmLactin 12% cream/lotion and U-Lactin lotion (2% lactic acid plus 10%
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         ) as well as prescription
         <a class="drug drug_general" data-topicid="10073" href="/z/d/drug information/10073.html" rel="external">
          ammonium lactate
         </a>
         12% lotion (Lac-Hydrin).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Salicylic acid is a beta-hydroxy acid that has the added benefit of softening and moisturizing the skin, in addition to desquamating the stratum corneum [
         <a href="#rid27">
          27,29
         </a>
         ]. Salicylic acid in concentrations up to 20% can be found over the counter [
         <a href="#rid7">
          7
         </a>
         ]. Compounded preparations with higher concentrations (up to 50%) are available by prescription and can be used for difficult-to-treat, limited body areas and for the palms and soles [
         <a href="#rid7">
          7
         </a>
         ]. Several 2% salicylic acid preparations are available over the counter. Examples of higher concentrations available by prescription are Keralyt (6%) gel and Salex (6%) lotion/cream. Salicylic acid is also easily compounded alone or with
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         (eg, salicylic acid 5 to 10% plus urea 5 to 10% in cream/ointment or, for plantar keratoderma, salicylic acid 50% plus urea 20% in petroleum).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neutrogena T/Sal or DHS Sal Shampoo Maximum Strength (3% salicylic acid) are keratolytic shampoos.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urea
         </strong>
         – Low-dose (10 to 20%) topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         preparations can be found over the counter. Compounded preparations with higher concentrations (up to 40% [eg, Carmol 40]) are available by prescription and can be used for difficult-to-treat, limited skin areas. In a small, randomized, right-left comparison trial that included 32 patients with ichthyosis vulgaris, a 10% urea lotion applied daily for four weeks was more effective than an emollient cream in reducing scaling, roughness, and fissures [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Propylene glycol
         </strong>
         – The use of aqueous propylene glycol 40 to 60% applied under occlusion was first described in patients with X-linked ichthyosis and ichthyosis vulgaris [
         <a href="#rid31">
          31
         </a>
         ]. Propylene glycol is a common ingredient in topical products but has been reported to cause allergic and irritant contact dermatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined preparations
         </strong>
         – Application of compounded 5% lactic acid with 20% propylene glycol or 6% salicylic acid with 60% propylene glycol in a fatty base can significantly decrease scaling in patients with autosomal recessive congenital ichthyosis, especially lamellar ichthyosis. The combination of salicylic acid and propylene glycol is also particularly helpful for the treatment of palmoplantar keratoderma [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Topical keratolytics are applied once or twice daily. Higher concentrations are typically needed for areas of severe involvement or thickening, such as the palms and soles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and precautions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infants &lt;6 months should not be exposed to keratolytic agents because of the risk of systemic absorption. Use in infants and young children should also be limited in extent, due to the high risk of systemic absorption relative to their body surface area. For this same reason, pediatric patients of all ages should be monitored when keratolytic agents are used to cover large surface areas for prolonged periods [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Special attention should be paid to patients using salicylic acid. Although rare, there have been documented cases of salicylism and even death from systemic absorption of topically applied salicylic acid [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Propylene glycol is a weak sensitizer and potential irritant [
         <a href="#rid37">
          37
         </a>
         ]. Toxicity from extensive application and transdermal absorption can induce agitation, cardiac arrhythmia or arrest, central nervous system toxicity, hyperosmolarity, hemolysis, lactic acidosis, and seizures [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In infants, topical urea-based preparations can elevate blood
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         nitrogen levels when applied to larger surface areas [
         <a href="#rid7">
          7,39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4287982055">
         <span class="h1">
          RETINOIDS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retinoids are analogues of vitamin A (all-
         <strong>
          trans
         </strong>
         retinol) that selectively bind to specific subunits of nuclear retinoic acid receptors (RARs) and modulate epidermal maturation, keratinocyte differentiation, apoptosis, immune function, and carcinogenesis. In ichthyosis, retinoids act principally as antikeratinizing agents, thus reducing hyperkeratosis and scaling. Retinoids are typically used in conjunction with the general measures outlined above and with copious use of emollients. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
         Because of the rarity of the congenital ichthyosis subtypes that benefit from treatment with retinoids, there is a lack of high-quality, large studies evaluating their efficacy and long-term adverse effects. Evidence supporting their use is mainly derived from small, observational studies and clinical experience. Expert consensus guidelines addressing the use of retinoids for the management of ichthyosis in children and adolescents have been published in Europe and the United States [
         <a href="#rid3">
          3,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3945709019">
         <span class="h2">
          Topical retinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical retinoids, including
         <a class="drug drug_general" data-topicid="9352" href="/z/d/drug information/9352.html" rel="external">
          adapalene
         </a>
         , topical
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         , tretinoin,
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         , and
         <a class="drug drug_general" data-topicid="122818" href="/z/d/drug information/122818.html" rel="external">
          trifarotene
         </a>
         , have a limited role in the management of ichthyosis [
         <a href="#rid3">
          3,41
         </a>
         ]. Tazarotene is used more frequently than lower-potency agents, such as tretinoin and adapalene  (
         <a class="graphic graphic_table graphicRef134117" href="/z/d/graphic/134117.html" rel="external">
          table 5
         </a>
         ). Trifarotene is a newer topical retinoid that specifically targets RAR-gamma. It is expressed more abundantly in the skin than RAR-alpha and RAR-beta and expressed less in other organs, potentially resulting in increased effectiveness and the reduced potential for systemic side effects [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="122818" href="/z/d/drug information/122818.html" rel="external">
          Trifarotene
         </a>
         is being evaluated in a phase 2, randomized, multicenter trial of adults and adolescents with lamellar ichthyosis (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03738800&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiR%2BbVn%2FjEqhLY0WtxcyJoFzZvMR0WXqwzmo3Z169CgUAg%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT03738800
         </a>
         ). Topical
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         is also being studied in a phase 2 clinical trial for patients nine years of age and older with recessive X-linked ichthyosis and lamellar ichthyosis subtypes (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04154293&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQPIHOBats9bPBxuETR8K%2BGjudzcoW%2FhF5V5pBUYSyegg%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT04154293
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         –
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          Tazarotene
         </a>
         has been successfully used to loosen areas of contracture in neonates and infants with harlequin ichthyosis [
         <a href="#rid43">
          43-46
         </a>
         ] and for the treatment of ectropion in children and adults with lamellar ichthyosis [
         <a href="#rid47">
          47,48
         </a>
         ] (see
         <a class="local">
          'Special sites'
         </a>
         below and
         <a class="local">
          'Harlequin ichthyosis'
         </a>
         below). Tazarotene has also been used in patients with recessive X-linked ichthyosis, lamellar ichthyosis, erythrokeratoderma variabilis, and neutral lipid storage disease with ichthyosis [
         <a href="#rid44">
          44,45,49-51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         should be initiated at the lowest therapeutic dose possible and titrated up, as tolerated, to achieve the desired effect. For example, some individuals with ichthyosis do well with topical retinoid application only once per week and become irritated with higher frequency use. Available in 0.05 and 0.1% creams and gels, tazarotene can also be mixed 1:3 to 1:1 with petrolatum at home to reduce the initial dose, allowing up-titration to full strength and promoting better tolerance. Areas of the body differ in their responsiveness. Dilution is useful for delicate areas (eg, the periorbital region), whereas higher concentrations may be needed for palmoplantar keratoderma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and precautions
         </strong>
         – Worsening erythema, irritation, and xerosis are common adverse reactions to topical retinoid treatment. Increased risk of sunburn has also been described with topical retinoid use. Due to their dose-dependent response, increasing potency may also increase associated adverse effects [
         <a href="#rid7">
          7
         </a>
         ]. However, tolerance is generally improved by slowly increasing the concentration and/or frequency of application. Concurrent use of emollients may mitigate xerosis [
         <a href="#rid52">
          52
         </a>
         ]. Temporary discontinuation of the retinoid and application of a topical corticosteroid may be needed for severe skin inflammation and discomfort.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are limited data regarding the safety of the use of topical retinoids in pregnancy and lactation. A meta-analysis of four observational studies comparing the outcome of 654 pregnancies exposed to topical retinoids with those of 1375 control (unexposed) pregnancies did not find an increased rate of major congenital malformations, spontaneous abortion, stillbirth, low birth weight, or prematurity associated with exposure to topical retinoids during the first trimester of pregnancy [
         <a href="#rid53">
          53
         </a>
         ]. Although pregnancy testing is unnecessary with use of topical retinoids, safety findings have not been confirmed in larger studies, and it is prudent to avoid using
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         during pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3110296992">
         <span class="h2">
          Systemic retinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         are the two oral retinoids available in the United States for the off-label treatment of ichthyosis. Oral
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         is available in Europe and Canada but not in the United States [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Systemic retinoids are indicated for
         <strong>
         </strong>
         patients with forms of ichthyosis who have severe and extensive scaling and hyperkeratosis that are insufficiently improved with topical therapies alone, in particular for patients with autosomal recessive congenital ichthyosis [
         <a href="#rid1">
          1,3
         </a>
         ]. Other rare subtypes of ichthyosis that can benefit from systemic retinoid therapy include recessive X-linked ichthyosis [
         <a href="#rid55">
          55
         </a>
         ], ichthyosis with confetti [
         <a href="#rid56">
          56
         </a>
         ], erythrokeratodermia variabilis [
         <a href="#rid57">
          57
         </a>
         ], KID (keratitis-ichthyosis-deafness) syndrome [
         <a href="#rid58">
          58,59
         </a>
         ], KLICK (keratosis linearis with ichthyosis congenita and sclerosing keratoderma) syndrome [
         <a href="#rid60">
          60
         </a>
         ], and Sjögren-Larsson syndrome [
         <a href="#rid61">
          61
         </a>
         ]. The response of different subtypes of ichthyosis to systemic retinoids is summarized in the table  (
         <a class="graphic graphic_table graphicRef134195" href="/z/d/graphic/134195.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of systemic retinoid
         </strong>
         –
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          Isotretinoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9366" href="/z/d/drug information/9366.html" rel="external">
          alitretinoin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         are all effective in removing scale and reducing hyperkeratosis, although response may vary in different types of ichthyosis  (
         <a class="graphic graphic_table graphicRef134195" href="/z/d/graphic/134195.html" rel="external">
          table 4
         </a>
         ) and in individual patients. Acitretin also improves hypohidrosis and ectropion in patients with lamellar ichthyosis and is beneficial for patients with epidermolytic ichthyosis with
         <em>
          KRT10
         </em>
         variants [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of one agent over the other is influenced by several factors, including type and severity of ichthyosis, age and sex of the patient, pharmacokinetic properties, safety profile, and consideration of pregnancy planning in female patients.
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          Isotretinoin
         </a>
         has a much shorter half-life than
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         and is cleared from the body within days to a few weeks of treatment discontinuation [
         <a href="#rid3">
          3
         </a>
         ]. Thus, for female patients of reproductive potential, isotretinoin remains the treatment of choice, and consideration should be given to switching young female patients being treated with acitretin to isotretinoin as they become closer to childbearing potential and sexually active [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnancy can occur safely one month after the last dose of
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         . In contrast, patients on
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         therapy must avoid pregnancy for a minimum of three years due to metabolic conversion of acitretin to etretinate as an effect of alcohol ingestion, long-term storage of etretinate in fat, and chronic release into the circulation [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – The optimal dose for systemic retinoids is the lowest dose required for obtaining the desired therapeutic effect with tolerable adverse effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         is formulated in capsule doses of 10 and 25 mg. The usual dose for acitretin is 0.5 to 1 mg/kg/day in both children and adults, with a maximum of 75 mg/day. Upon achieving a satisfactory response, the dose can be tapered to the lowest dose necessary to maintain improvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          Isotretinoin
         </a>
         is formulated in capsule doses of 10, 20, 30, and 40 mg. Guidelines recommend initiation at 1 mg/kg/day and reduction to maintenance dosing of 0.5 to 1 mg/kg/day. Intermittent dosing or "retinoid holidays" do not result in rebound flares. Thus, temporary discontinuation and cyclic use may mitigate adverse effects and increase adherence to treatment in many patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tips for administering retinoid capsules to children [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Capsules should be used immediately upon removal from their package, kept out of direct sunlight, and administered with high-fat foods (eg, whole milk, ice cream, or peanut or other nut butter) for best absorption.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Capsules can be swallowed whole or chewed. They can be frozen within bite-sized, soft-centered chocolate for tastier chewing in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For infants or younger children, a hole can be poked in the capsule with a sharp knife or nail clippers and the powder added directly to food or a small amount of breast milk or formula (15 to 30 mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects and precautions
         </strong>
         – Much of our understanding about the potential risks associated with systemic retinoid treatment is based on studies of
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         for acne and
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         for psoriasis. The toxicity of long-term systemic use in children with disorders of cornification has not been well studied. In a cohort of 174 children (94 with congenital ichthyosis) treated with acitretin for an average of 3.5 years, clinical and laboratory adverse events, all reversible, occurred in 24 percent of patients and led to permanent cessation of treatment in 10 percent of patients [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Common adverse effects
         </strong>
         – The most common side effects of systemic retinoids are cheilitis (virtually 100 percent), increased skin dryness and irritation, skin fragility, and xerosis of mucous membranes. Elevation of fasting levels of lipids, especially triglycerides, is the most common metabolic adverse event [
         <a href="#rid3">
          3,65,66
         </a>
         ], but in most cases, lipid-lowering treatment is not required. However, in patients on long-term retinoid treatment who persistently have elevated lipid levels of clinical importance, retinoid treatment can be continued in combination with lipid-lowering agents [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">
          "Dyslipidemia in children and adolescents: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">
          "Hypertriglyceridemia in adults: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Headaches, vision changes, hepatotoxicity, arthralgias, and bone changes are uncommon but should be monitored  (
         <a class="graphic graphic_table graphicRef134117" href="/z/d/graphic/134117.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid3">
          3,65
         </a>
         ]. Pseudotumor cerebri (idiopathic intercranial hypertension) is a rare adverse event [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Psychiatric issues
         </strong>
         – Psychiatric issues are a recognized comorbidity of ichthyosis, with 34 percent of adults and 30 percent of children screening positive for depression and 27 percent of adults and 37 percent of children screening positive for anxiety [
         <a href="#rid68">
          68
         </a>
         ]. Although depression has been mentioned as a potential adverse effect of the use of
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         , depression and suicidal ideation associated with isotretinoin use for acne in teenagers and young adults is thought to be primarily related to the age of the patients and the psychologic impact of acne [
         <a href="#rid66">
          66,69
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/38.html" rel="external">
          "Oral isotretinoin therapy for acne vulgaris", section on 'Psychiatric effects'
         </a>
         ). In patients with ichthyosis, the potential benefit of effective disease management with retinoids on psychosocial functioning and quality of life is important. That said, psychiatric monitoring for the development of psychiatric symptoms is recommended in patients on systemic retinoids [
         <a href="#rid3">
          3
         </a>
         ]. If there is any concern, partnership with a behavioral health provider to formulate a treatment plan that addresses mental health concerns as well as ichthyosis treatment is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnancy
         </strong>
         – Pregnancy is contraindicated with the use of systemic retinoids because they are known teratogens. Boxed warnings for systemic retinoids indicate extreme risk of severe, congenital anomalies in exposed fetuses. With the use of systemic retinoids, patients must use two forms of contraceptives simultaneously if they are sexually active (abstinence is acceptable), one of which should be considered highly effective (eg, an intrauterine device). In addition, in the United States, all patients on
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         must commit to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fipledgeprogram.com%2F%23Main&amp;token=11npaxc5%2BtwYQNEbNxIvNQfcJaSKzBwVKphwr4ut8b7qoeyGYSAd9yUzO5kFibik&amp;TOPIC_ID=128456" target="_blank">
          iPLEDGE
         </a>
         program designed to prevent pregnancy and eliminate fetal exposure to isotretinoin. (See
         <a class="medical medical_review" href="/z/d/html/38.html" rel="external">
          "Oral isotretinoin therapy for acne vulgaris", section on 'iPLEDGE program'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4232238781">
         <span class="h1">
          OTHER THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other therapies that have been tried in a limited number of patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical N-
         </strong>
         <strong>
          acetylcysteine
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          N-acetylcysteine
         </a>
         (NAC) was first reported to improve lamellar ichthyosis when used twice daily and, since then, has also been found to be helpful for patients with other forms of ichthyosis [
         <a href="#rid70">
          70-72
         </a>
         ]. Although its advantage is minimal systemic absorption (3 percent systemic bioavailability), NAC may cause irritation and/or increased scaling and has a foul, sulfuric odor that is difficult to mask [
         <a href="#rid71">
          71,72
         </a>
         ]. It also needs compounding (typically as 5 to 10% NAC in 5%
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         ), is costly, and is often not covered by insurance [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical
         </strong>
         <strong>
          carbocysteine
         </strong>
         – A formulation combining 10% carbocysteine and 5%
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         was used to treat three children (ages five to nine years) with autosomal recessive congenital ichthyosis and one adult with ichthyosis vulgaris, with clinical effectiveness in three out of the four patients [
         <a href="#rid73">
          73
         </a>
         ]. Since the carbocysteine molecule is like NAC but has a bound sulfhydryl group rather than a free one, it lacks the foul smell that NAC-compounded formulations emit. This is especially advantageous for treatment compliance and may help improve quality of life from a social perspective. No adverse effects were reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin D
         </strong>
         – Ichthyoses, especially epidermolytic ichthyosis and autosomal recessive congenital ichthyosis, have been associated with an increased risk of vitamin D deficiency and rickets [
         <a href="#rid74">
          74,75
         </a>
         ]. Proposed mechanisms include decreased ultraviolet (UV) light exposure, inability of ultraviolet B (UVB) radiation to penetrate thick scale, or a keratinocyte abnormality in processing
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          vitamin D3
         </a>
         in response to UVB radiation [
         <a href="#rid76">
          76
         </a>
         ]. Vitamin D levels should be monitored, and adjunct therapy with vitamin D3 should be implemented for anyone with a deficiency. (See
         <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">
          "Vitamin D insufficiency and deficiency in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small case series, seven children with congenital ichthyosis and severe vitamin D deficiency (serum 25(OH)D &lt;4 ng/mL), of whom six had clinical and radiologic evidence of rickets, were treated with a 10-day course of high-dose vitamin D3 (60,000 international units daily) plus 40 mg/kg/day of elemental calcium, followed by daily supplementation of 400 to 600 international units of
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          cholecalciferol
         </a>
         (recommended daily allowance) [
         <a href="#rid77">
          77
         </a>
         ]. Six of seven children experienced improvement in scaling and skin stiffness after five days of beginning treatment. Hypercalcemia developed in one patient. Whether vitamin D oral supplementation at the recommended doses for the treatment of nutritional rickets [
         <a href="#rid78">
          78
         </a>
         ] is beneficial for children with congenital ichthyosis has not been determined. (See
         <a class="medical medical_review" href="/z/d/html/14590.html" rel="external">
          "Vitamin D insufficiency and deficiency in children and adolescents", section on 'Vitamin D replacement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical vitamin D analogues
         </strong>
         – Data are limited on the use and effectiveness of topical synthetic vitamin D analogs (
         <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">
          calcipotriol
         </a>
         and calcipotriene) for treating disorders of cornification, but case reports suggest some response in patients with lamellar ichthyosis, epidermolytic ichthyosis, recessive X-linked ichthyosis, and Netherton syndrome [
         <a href="#rid7">
          7,79-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3019646158">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3685219652">
         <span class="h2">
          Harlequin ichthyosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         As is the standard of care for collodion babies, neonates with harlequin ichthyosis should be treated in neonatal intensive care units and placed in an isolette with 50 to 70 percent humidification to allow for proper temperature regulation and prevention of excess transepidermal water loss. (See
         <a class="medical medical_review" href="/z/d/html/112583.html" rel="external">
          "Autosomal recessive congenital ichthyoses", section on 'Neonates with harlequin ichthyosis'
         </a>
         .)
        </p>
        <p>
         Careful and close monitoring of body weight, hydration status, and electrolyte balance is important. Prophylactic initiation of systematic antibiotics is not recommended, but careful observation for signs and symptoms of sepsis is required. Given the poor cutaneous barrier and potential toxicity, use of keratolytic agents should be avoided during infancy in all neonates and younger infants with ichthyosis [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         In harlequin ichthyosis specifically, early initiation of systemic retinoids should be considered, particularly if there are digital and/or thoracic contractures [
         <a href="#rid82">
          82
         </a>
         ].
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          Acitretin
         </a>
         is the oral retinoid of choice. It can be compounded by breaking the capsule and mixing the powder with a small amount of formula or breast milk [
         <a href="#rid83">
          83
         </a>
         ]. The suggested dosing is 0.5 to 1 mg/kg once daily. Topical application of
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         , or surgical lysis if indicated, can also quickly reduce the digital encasing bands (pseudoainhum), which can otherwise lead to digital and limb constriction [
         <a href="#rid46">
          46,83
         </a>
         ]. Retinoids may be tapered and discontinued by six months of age in many affected babies, with continued use of topical retinoids as needed [
         <a href="#rid83">
          83,84
         </a>
         ]. Pain control with
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         or opioids may be necessary [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H269664517">
         <span class="h2">
          Fungal infection of the skin and hair
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with ichthyosis are prone to develop dermatophyte infection, which may not be recognized during routine care. In the presence of suddenly worsening alopecia or localized scaling and erythema, the presence of intercurrent fungus infection should be considered.
        </p>
        <p class="headingAnchor" id="H889696545">
         <span class="h2">
          Special sites
         </span>
        </p>
        <p class="headingAnchor" id="H2932149826">
         <span class="h3">
          Eyes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Special attention should be given to eye care for patients with ectropion [
         <a href="#rid85">
          85
         </a>
         ]. Preservative-free eye lubricant ointments, and potentially eye shield use at night, are critical for those who cannot fully close the eyes to avoid keratitis [
         <a href="#rid1">
          1,5
         </a>
         ]. Early and routine ophthalmology evaluation is recommended. A small case series and a case report showed improvement and, in some cases, complete reversal of ectropion with daily or twice-daily application of
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         0.05 to 0.1% cream [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         Surgical correction for contracture release and grafting with autologous skin or engineered human skin is generally reserved for severe cases [
         <a href="#rid86">
          86-88
         </a>
         ]. Although good results have been reported after surgery, patients may still have difficulty in fully closing the eye, and cosmetic results may not be perfect. Systemic retinoids may be an alternative to surgery or may be given following surgery to prevent recurrence [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H495932783">
         <span class="h3">
          Ears
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accumulation of debris can lead to conductive hearing loss [
         <a href="#rid5">
          5
         </a>
         ]. Early evaluation and removal of debris by a professional every 3 to 12 months, as needed, is important, particularly in infants and young children who are developing speech skills [
         <a href="#rid89">
          89
         </a>
         ].
         <a class="drug drug_general" data-topicid="9277" href="/z/d/drug information/9277.html" rel="external">
          Acetic acid
         </a>
         0.25%,
         <a class="drug drug_general" data-topicid="95641" href="/z/d/drug information/95641.html" rel="external">
          aluminum acetate
         </a>
         2%, or over-the-counter ear wax removal drops can help soften keratin plugs [
         <a href="#rid83">
          83
         </a>
         ]. External otitis occurs more often in individuals with ichthyosis. Treatment with a 7- to 10-day course of topical antibiotics with or without a steroid component is usually effective. (See
         <a class="medical medical_review" href="/z/d/html/16516.html" rel="external">
          "External otitis: Treatment", section on 'Topical otic preparations: General principles'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4202257758">
         <span class="h3">
          Extremity contractures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular physical therapy should be prescribed in conjunction with topical or systemic retinoid treatment [
         <a href="#rid5">
          5,46,83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3671659826">
         <span class="h1">
          TARGETED AND INVESTIGATIONAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The discovery of the genetic alterations underlying the inherited disorders of keratinization and an evolving understanding of the implicated pathogenetic mechanisms promoted efforts to develop pathogenesis-based therapies for this group of genodermatoses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Compounded topical statin-cholesterol
         </strong>
         – There are a few case reports of successful use of compounded topical statin-cholesterol for the treatment of the skin manifestations of CHILD (congenital hemidysplasia with ichthyosiform erythroderma and limb defects) syndrome [
         <a href="#rid90">
          90-92
         </a>
         ] and porokeratosis [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CHILD syndrome is a rare, X-linked dominant disorder caused by a variant in
         <em>
          NSDHL
         </em>
         , encoding NAD(P) sterol dehydrogenase-like, a key enzyme in the cholesterol biosynthesis pathway [
         <a href="#rid95">
          95
         </a>
         ]. The accumulation of toxic sterol precursors is primarily responsible for the abnormal cornification and skin barrier function, likely exacerbated by reduction of cholesterol in the barrier. Targeted treatment for cutaneous manifestations using compounded 2%
         <a class="drug drug_general" data-topicid="9575" href="/z/d/drug information/9575.html" rel="external">
          lovastatin
         </a>
         /2% cholesterol ointment prevents toxic metabolite formation and replenishes cholesterol, leading to rapid improvement in skin erythema and scaling [
         <a href="#rid90">
          90
         </a>
         ]. The use of alternative statins (eg, topical
         <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">
          simvastatin
         </a>
         ) compounded with cholesterol and the combination with topical glycolic acid have also been reported as beneficial [
         <a href="#rid91">
          91,92,96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">
          "Overview and classification of the inherited ichthyoses", section on 'X-linked dominant disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Porokeratosis includes a group of disorders of cornification characterized by the cornoid lamella histologically and leading to a specific pattern of scaling. Gene variants all involve the mevalonate components of the cholesterol biosynthesis pathway, upstream of the
         <em>
          NSDHL
         </em>
         product. Similar to CHILD syndrome, targeted treatment with 2% statin/2% cholesterol can improve disseminated superficial actinic porokeratosis, porokeratosis palmaris et plantaris disseminate, and linear porokeratosis [
         <a href="#rid93">
          93,94
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">
          "Porokeratosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biologics
         </strong>
         – Studies have shown strong interleukin (IL) 17/tumor necrosis factor (TNF)-alpha cytokine activation in the skin and blood of patients with severe types of congenital ichthyosis (eg, autosomal recessive congenital ichthyosis, keratinopathic ichthyosis, and Netherton syndrome) similar to that seen in psoriasis [
         <a href="#rid97">
          97-100
         </a>
         ]. These findings have led to a proposal for repurposing targeted therapies used for psoriasis and atopic dermatitis for the treatment of rare, severe forms of ichthyosis [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secukinumab
         </strong>
         <strong>
          and
         </strong>
         <strong>
          ustekinumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">
          Secukinumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         are inhibitors of IL-17 and IL-12/IL-23 pathways, respectively. Both agents induced remarkable improvement in some, but not all, treated patients with Netherton syndrome [
         <a href="#rid102">
          102,103
         </a>
         ] and congenita ichthyosiform erythroderma [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          Ustekinumab
         </a>
         was also successfully used in two patients with erythrokeratodermia-cardiomyopathy (EKC) syndrome, an autosomal dominant, ichthyotic disorder presenting in infancy with failure to thrive, dental and nail anomalies, woolly hair with alopecia, and the development of life-threatening cardiomyopathy [
         <a href="#rid105">
          105,106
         </a>
         ].
         <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">
          Secukinumab
         </a>
         improved skin manifestations, growth, and quality of life in two patients with SAM (severe dermatitis, multiple allergies, and metabolic wasting) syndrome, a rare genodermatosis characterized by congenital erythroderma and striate palmoplantar keratoderma and associated with a dysregulation of the IL-17 pathway [
         <a href="#rid107">
          107,108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">
          "Peeling skin syndromes", section on 'SAM syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A clinical trial of
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         in children and adults with ichthyosis is ongoing (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04549792&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQkRCpfquYEiG9CmOefDPz%2FqGNQaMztF13quBVQec3srA%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT04549792
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dupilumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          Dupilumab
         </a>
         , an anti-IL-4 receptor-alpha antibody approved for treating atopic dermatitis, has been shown to reduce erythema and scaling in a few patients with Netherton syndrome [
         <a href="#rid109">
          109-113
         </a>
         ]. Clinical trials of dupilumab for Netherton syndrome and other congenital ichthyoses are underway (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04244006&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRoGuyevdBfoPAD7CpW8NHFwU8ntYHw5hLXWXNmGizCGQ%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT04244006
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04996485&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQ34Dh7Bnv1LHvcDDWTwvBm%2FqyD1UAco6gncp6wxDiE2Q%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT04996485
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infliximab
         </strong>
         – Based on the demonstration of increased TNF-alpha expression in Netherton syndrome skin,
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         therapy led to reduced erythema in one patient, but the xerosis, scaling, and high serum immunoglobulin E (IgE) levels did not improve [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Omalizumab
         </strong>
         – In one patient with Netherton syndrome, a four-month course of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy in conjunction with pulse
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and antihistamines led to decreased pruritus, erythema, desquamation, and mucosal symptoms within four weeks [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ixekizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">
          Ixekizumab
         </a>
         , a humanized anti-IL-17A/F antibody, induced substantial improvement of the inflammatory skin lesions in two of three patients with Netherton syndrome after six months of treatment [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gene therapy
         </strong>
         – Gene therapy trials with grafts of autologous keratinocytes transduced with the normal
         <em>
          SPINK5
         </em>
         gene using a lentivirus vector are ongoing in patients with Netherton syndrome (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT01545323&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQswz15KjEb2F360ROVRGswONt%2FSvJw02lObeykV51jgg%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT01545323
         </a>
         ) [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A trial of topical application of
         <em>
          TGM1
         </em>
         (the gene encoding transglutaminase 1) inserted as multiple copies into an inactivated herpes simplex virus in adult patients with lamellar ichthyosis who carry a null
         <em>
          TGM1
         </em>
         variant is also underway (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04047732&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiToJ1CjpNfkyB8sSVTPMo6lU%2FaZhHbK3SwrDEQn4yCgaQ%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          NCT04047732
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1657645139">
         <span class="h1">
          PATIENT SUPPORT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disorders of cornification have a negative impact on the quality of life and psychosocial well-being for patients and their families/caregivers [
         <a href="#rid119">
          119
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=128456" target="_blank">
          Foundation for Ichthyosis and Related Skin Types (FIRST)
         </a>
         hosts meetings for patient interactions and provides educational materials and information on available treatment options. A listing of over-the-counter products, created by FIRST in collaboration with patients and families/caregivers, can be provided to clinicians and members of the organization upon request.
        </p>
        <p>
         Other foundations that support the families/caregivers of patients with ichthyosis include the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fichthyosis.info%2F&amp;token=aYWAT0VJwfgbOtQE0kSiA7Eiw3myF4Au0P16DeWfO8ivALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128456" target="_blank">
          European Network for Ichthyosis
         </a>
         , the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ichthyosis.org.uk%2F&amp;token=xFYUVan6gjv%2B4sGZwbFp8vbG86lId9lD6%2FCsoVKHVcgPBF2eql%2Bu1zY%2Fw6cx%2FTRN&amp;TOPIC_ID=128456" target="_blank">
          Ichthyosis Support Group
         </a>
         (United Kingdom), and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ictiosis.org%2F&amp;token=xFYUVan6gjv%2B4sGZwbFp8orsf3nkt%2B1KWqDxpGNfjTFA%2BdTBrfHMx9H3uzo%2FHssr&amp;TOPIC_ID=128456" target="_blank">
          Asociación Española de Ictiosis
         </a>
         (Spain).
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fpublic%2Fpublic-health%2Fcamp-discovery&amp;token=IQxLzDq4doJGUgaZgeIY01Nfcry0vAq5JxqPRXUQzcK%2B2zuc8M33VZgh7K4tZs3yiQLEHG8S1HQKfivLReHHOQ%3D%3D&amp;TOPIC_ID=128456" target="_blank">
          Camp Discovery
         </a>
         is a week-long opportunity for children and adolescents with hair and skin disorders, including disorders of cornification, sponsored by the American Academy of Dermatology.
        </p>
        <p class="headingAnchor" id="H1251165030">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/129484.html" rel="external">
          "Society guideline links: Ichthyosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3445489773">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of treatment
         </strong>
         – There are no curative therapies for ichthyosis. Treatment is largely symptomatic, aimed at reducing skin dryness and scaling, limiting excess transepidermal water loss, hydrating and softening the stratum corneum, and controlling skin inflammation and pruritus. Because of the chronic nature of these disorders, patients require long-term, comprehensive care. For patients with severe disease, early consultation with a multidisciplinary team (including dermatology, genetics, neonatology, ophthalmology, otolaryngology, orthopedic and plastic surgery, occupational and physical therapy, and nutrition) is essential. (See
         <a class="local">
          'General considerations'
         </a>
         above and
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General measures
         </strong>
         – General skin care measures, including bathing, exfoliation, and liberal use of emollients, are the mainstay of ichthyosis management. Long, daily baths with additives (eg,
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         , bleach,
         <a class="drug drug_general" data-topicid="9277" href="/z/d/drug information/9277.html" rel="external">
          acetic acid
         </a>
         ) facilitate scale removal, reduce bacterial colonization and odor, and hydrate the skin. (See
         <a class="local">
          'General measures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical therapies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical keratolytics
         </strong>
         – Topical keratolytic agents are first-line treatment for children and adults with ichthyosis. Creams and ointments containing alpha-hydroxy acids, beta-hydroxy acids,
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         , and propylene glycol, in various concentrations and combinations, are commonly used with good response in most types of ichthyosis  (
         <a class="graphic graphic_table graphicRef134195" href="/z/d/graphic/134195.html" rel="external">
          table 4
         </a>
         ). Topical keratolytics are contraindicated in infants younger than six months and should be used with caution in older infants and children due to the risk of adverse effects from systemic absorption. (See
         <a class="local">
          'Topical keratolytic agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical retinoids
         </strong>
         –
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          Tazarotene
         </a>
         , the most potent topical retinoid, is the preferred topical retinoid for the scaling of ichthyosis and is the preferred first-line agent for treating ectropion in lamellar ichthyosis. Tazarotene can also be used to loosen areas of contracture in neonates and infants with harlequin ichthyosis. (See
         <a class="local">
          'Topical retinoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic retinoids
         </strong>
         – Systemic retinoids (
         <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">
          acitretin
         </a>
         and
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         ) are indicated for patients with severe and extensive scaling and hyperkeratosis that are insufficiently improved with topical therapies alone  (
         <a class="graphic graphic_table graphicRef134195" href="/z/d/graphic/134195.html" rel="external">
          table 4
         </a>
         ). Both acitretin and isotretinoin are initiated at a dose of 0.5 to 1 mg/kg/day, with subsequent adjustments to the lowest dose required for obtaining the desired therapeutic effect with tolerable adverse effects. Systemic retinoids are teratogenic. Because of its shorter half-life and more rapid clearance, isotretinoin is preferred to acitretin for the treatment of female patients of childbearing potential. (See
         <a class="local">
          'Systemic retinoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Targeted therapies
         </strong>
         – Improved understanding of the underlying pathogenesis of ichthyoses, beyond the gene variants, has led to the emergence of pharmacologic, pathogenesis-based approaches. Targeted treatment with topical statin-cholesterol greatly improves the skin manifestations of CHILD (congenital hemidysplasia with ichthyosiform erythroderma and limb defects) syndrome and porokeratosis. Repurposing of biologic agents, such as interleukin (IL) 23/T helper type 17 (Th17) pathway inhibitors
         <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">
          secukinumab
         </a>
         and
         <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">
          ustekinumab
         </a>
         , has improved inflammation and scale in a subset of patients with erythrodermic forms (eg, congenital ichthyosiform erythroderma, Netherton syndrome, erythrokeratodermia-cardiomyopathy [EKC] syndrome, and SAM [severe dermatitis, multiple allergies, and metabolic wasting] syndrome). (See
         <a class="local">
          'Targeted and investigational therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Online resources for patients with ichthyosis and their families/caregivers include the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2F&amp;token=oN6rXOmeBLkIpfIsq5mH5Z0Le%2Fvc5VRvejbPvZqw%2FIYldSRDD4QEGzmgJ%2BviBi8p&amp;TOPIC_ID=128456" target="_blank">
          Foundation for Ichthyosis and Related Skin Types (FIRST)
         </a>
         , the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fichthyosis.info%2F&amp;token=aYWAT0VJwfgbOtQE0kSiA7Eiw3myF4Au0P16DeWfO8ivALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128456" target="_blank">
          European Network for Ichthyosis
         </a>
         , the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ichthyosis.org.uk%2F&amp;token=xFYUVan6gjv%2B4sGZwbFp8vbG86lId9lD6%2FCsoVKHVcgPBF2eql%2Bu1zY%2Fw6cx%2FTRN&amp;TOPIC_ID=128456" target="_blank">
          Ichthyosis Support Group
         </a>
         , and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ictiosis.org%2F&amp;token=xFYUVan6gjv%2B4sGZwbFp8orsf3nkt%2B1KWqDxpGNfjTFA%2BdTBrfHMx9H3uzo%2FHssr&amp;TOPIC_ID=128456" target="_blank">
          Asociación Española de Ictiosis
         </a>
         . (See
         <a class="local">
          'Patient support'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Digiovanna JJ, Mauro T, Milstone LM, et al. Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther 2013; 26:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivich JM. Ichthyosis in the Neonatal Setting. Adv Neonatal Care 2015; 15:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL, Levy ML, Stefanko NS, et al. Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol 2021; 38:164.
          </a>
         </li>
         <li class="breakAll">
          The Foundation for Ichthyosis and Related Skin Types. Skin Care Tips. https://www.firstskinfoundation.org/skin-care-tips (Accessed on August 17, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traupe H, Burgdorf WH. Treatment of ichthyosis–There is always something you can do! In Memoriam: Wolfgang Küster. J Am Acad Dermatol 2007; 57:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milstone LM. Scaly skin and bath pH: rediscovering baking soda. J Am Acad Dermatol 2010; 62:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleckman P, Newell BD, van Steensel MA, Yan AC. Topical treatment of ichthyoses. Dermatol Ther 2013; 26:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epps RE. Atopic dermatitis and ichthyosis. Pediatr Rev 2010; 31:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer TS. Dry skin and skin moisturizers. Clin Dermatol 1988; 6:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Draelos ZD. Active agents in common skin care products. Plast Reconstr Surg 2010; 125:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czarnowicki T, Malajian D, Khattri S, et al. Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer. J Allergy Clin Immunol 2016; 137:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller A, Tham K, Lefferdink RL, et al. The distinct skin microbiota of congenital ichthyoses. J Invest Dermatol 2021; 141:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evangelista MT, Abad-Casintahan F, Lopez-Villafuerte L. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial. Int J Dermatol 2014; 53:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis 2008; 19:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danby SG, AlEnezi T, Sultan A, et al. Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care. Pediatr Dermatol 2013; 30:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight TE, Hausen BM. Melaleuca oil (tea tree oil) dermatitis. J Am Acad Dermatol 1994; 30:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Groot AC, Schmidt E. Tea tree oil: contact allergy and chemical composition. Contact Dermatitis 2016; 75:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Palma AM, Mazereeuw-Hautier J, Giehl K, et al. Burden of itch in ichthyosis: a multicentre study in 94 patients. J Eur Acad Dermatol Venereol 2019; 33:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynertson KA, Garay M, Nebus J, et al. Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin. J Drugs Dermatol 2015; 14:43.
          </a>
         </li>
         <li class="breakAll">
          The National Foundation for Ectodermal Dysplasias. Don't Sweat? Here's What You Need To Know. https://www.nfed.org/blog/dont-sweat-heres-what-you-need-to-know/ (Accessed on August 29, 2021).
         </li>
         <li class="breakAll">
          The Foundation for Ichthyosis and Related Skin Types. Overheating. https://www.firstskinfoundation.org/overheating (Accessed on August 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haenssle HA, Finkenrath A, Hausser I, et al. Effective treatment of severe thermodysregulation by oral retinoids in a patient with recessive congenital lamellar ichthyosis. Clin Exp Dermatol 2008; 33:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saraçoğlu ZN, Tekin N, Urer SM, et al. Oral acitretin treatment in severe congenital ichthyosis of the neonate. Turk J Pediatr 2002; 44:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rawlings AV, Davies A, Carlomusto M, et al. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function. Arch Dermatol Res 1996; 288:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Marzio L, Centi C, Cinque B, et al. Effect of the lactic acid bacterium Streptococcus thermophilus on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients. Exp Dermatol 2003; 12:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lew LC, Liong MT. Bioactives from probiotics for dermal health: functions and benefits. J Appl Microbiol 2013; 114:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Scott EJ, Yu RJ. Control of keratinization with alpha-hydroxy acids and related compounds. I. Topical treatment of ichthyotic disorders. Arch Dermatol 1974; 110:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxman M, Hickman J, Ragsdale W, et al. Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream. J Am Acad Dermatol 1986; 15:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubeiz N, Kibbi AG. Management of ichthyosis in infants and children. Clin Dermatol 2003; 21:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tadini G, Giustini S, Milani M. Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. Curr Med Res Opin 2011; 27:2279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldsmith LA, Baden HP. Propylene glycol with occlusion for treatment of ichthyosis. JAMA 1972; 220:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gånemo A, Virtanen M, Vahlquist A. Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations. Br J Dermatol 1999; 141:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baden HP, Alper JC. A keratolytic gel containing salicylic acid in propylene glycol. J Invest Dermatol 1973; 61:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez ME, Youseef WF, Romero RG, et al. Acute percutaneous lactic acid poisoning in a child. Pediatr Dermatol 2006; 23:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaretti A, Schembri Wismayer D, Tortorolo L, et al. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol 2014; 70:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGowan MA, Scheman A, Jacob SE. Propylene Glycol in Contact Dermatitis: A Systematic Review. Dermatitis 2018; 29:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fligner CL, Jack R, Twiggs GA, Raisys VA. Hyperosmolality induced by propylene glycol. A complication of silver sulfadiazine therapy. JAMA 1985; 253:1606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garty BZ. High plasma urea concentration in babies with lamellar ichthyosis. Arch Dis Child 1986; 61:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beverley DW, Wheeler D. High plasma urea concentrations in collodion babies. Arch Dis Child 1986; 61:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol 2019; 180:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosio T, Di Prete M, Gaziano R, et al. Trifarotene: A Current Review and Perspectives in Dermatology. Biomedicines 2021; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behera B, Chandrashekar L, Singh N, et al. Lamellar ichthyosis associated bilateral pseudoainhum of fingers and toes successfully treated with tazarotene. Dermatol Ther 2017; 30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marulli GC, Campione E, Chimenti MS, et al. Type I lamellar ichthyosis improved by tazarotene 0.1% gel. Clin Exp Dermatol 2003; 28:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo S, Simzar S, Han K, et al. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Pediatr Dermatol 2006; 23:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu RH, Becker B, Gunkel J, Teng J. Rapid improvement in digital ischemia and acral contracture in a collodion baby treated with topical tazarotene. J Drugs Dermatol 2010; 9:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson B, Becker L, Hook K, et al. Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis. Pediatr Dermatol 2017; 34:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craiglow BG, Choate KA, Milstone LM. Topical tazarotene for the treatment of ectropion in ichthyosis. JAMA Dermatol 2013; 149:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999; 141:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotellessa C, Cuevas-Covarrubias SA, Valeri P, et al. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene. Acta Derm Venereol 2005; 85:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niculescu L, Ruini C, Srour J, et al. Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome. Acta Derm Venereol 2019; 99:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Dermatol 2006; 5:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan YC, Ozsarfati J, Etwel F, et al. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol 2015; 173:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blair HA, Scott LJ. Alitretinoin: A Review in Severe Chronic Hand Eczema. Drugs 2016; 76:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruckner-Tuderman L, Sigg C, Geiger JM, Gilardi S. Acitretin in the symptomatic therapy for severe recessive x-linked ichthyosis. Arch Dermatol 1988; 124:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra L, Diociaiuti A, El Hachem M, et al. Ichthyosis with confetti: clinics, molecular genetics and management. Orphanet J Rare Dis 2015; 10:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham-Brown RA, Chave TA. Acitretin for erythrokeratodermia variabilis in a 9-year-old girl. Pediatr Dermatol 2002; 19:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel V, Sun G, Dickman M, et al. Treatment of keratitis-ichthyosis- deafness (KID) syndrome in children: a case report and review of the literature. Dermatol Ther 2015; 28:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe CM, Davis A, Shaath TS, Cohen GF. Visual impairment reversal with oral acitretin therapy in keratitis-ichthyosis-deafness (KID) syndrome. JAAD Case Rep 2017; 3:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onnis G, Bourrat E, Jonca N, et al. KLICK syndrome: an unusual phenotype. Br J Dermatol 2018; 178:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vural S, Vural A, Akçimen F, et al. Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome. Int J Dermatol 2018; 57:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Virtanen M, Gedde-Dahl T Jr, Mörk NJ, et al. Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. Acta Derm Venereol 2001; 81:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brazzell RK, Colburn WA. Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. J Am Acad Dermatol 1982; 6:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cave A, Plumptre I, Mellerio JE, et al. The adverse effect profile of acitretin in a pediatric dermatology population-Longitudinal cohort study and recommendations for monitoring. J Am Acad Dermatol 2020; 83:1779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol 2018; 178:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkar S, Das K, Roychoudhury S, Shrimal A. Pseudotumor cerebri in a child treated with acitretin: a rare occurrence. Indian J Pharmacol 2013; 45:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Q, Ren I, Zaki T, et al. Ichthyosis affects mental health in adults and children: A cross-sectional study. J Am Acad Dermatol 2020; 83:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redondo P, Bauzá A. Topical N-acetylcysteine for lamellar ichthyosis. Lancet 1999; 354:1880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassotti A, Moreno S, Criado E. Successful treatment with topical N-acetylcysteine in urea in five children with congenital lamellar ichthyosis. Pediatr Dermatol 2011; 28:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan L, Castelo-Soccio L. Topical N-acetylcysteine in ichthyosis: Experience in 18 patients. Pediatr Dermatol 2018; 35:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batalla A, Dávila-Pousa C, Feal C, Flórez Á. Topical carbocysteine: A new option for the treatment of ichthyosis. Pediatr Dermatol 2018; 35:e357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingen-Housz-Oro S, Boudou P, Bergot C, et al. Evidence of a marked 25-hydroxyvitamin D deficiency in patients with congenital ichthyosis. J Eur Acad Dermatol Venereol 2006; 20:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethuraman G, Khaitan BK, Dash SS, et al. Ichthyosiform erythroderma with rickets: report of five cases. Br J Dermatol 2008; 158:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chouhan K, Sethuraman G, Gupta N, et al. Vitamin D deficiency and rickets in children and adolescents with ichthyosiform erythroderma in type IV and V skin. Br J Dermatol 2012; 166:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethuraman G, Marwaha RK, Challa A, et al. Vitamin D: A New Promising Therapy for Congenital Ichthyosis. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munns CF, Shaw N, Kiely M, et al. Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 2016; 101:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godic A, Dragos V. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur J Dermatol 2004; 14:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucker GP, van de Kerkhof PC, van Dïjk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994; 131:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thacher TD, Fischer PR, Pettifor JM, Darmstadt GL. Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics 2004; 114:e119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajpopat S, Moss C, Mellerio J, et al. Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases. Arch Dermatol 2011; 147:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glick JB, Craiglow BG, Choate KA, et al. Improved Management of Harlequin Ichthyosis With Advances in Neonatal Intensive Care. Pediatrics 2017; 139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyer JA, Spraker M, Williams M. Care of the newborn with ichthyosis. Dermatol Ther 2013; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson AH, Amato MM, Popham J. Ophthalmic Consequences of Ichthyosis and the Role of Systemic Retinoids. Ophthalmic Plast Reconstr Surg 2021; 37:e39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua CN, Ainsworth J. Ocular management of harlequin syndrome. Arch Ophthalmol 2001; 119:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culican SM, Custer PL. Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin. Am J Ophthalmol 2002; 134:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karadağ R, Sevimli N, Karadağ AS, Wollina U. Successful correction of ichthyosis-related ectropion by autografts. Dermatol Ther 2020; 33:e13851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JT, Mallon K, Hamill S, et al. Frequency of ear symptoms and hearing loss in ichthyosis: a pilot survey study. Pediatr Dermatol 2014; 31:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller AS, van Steensel MA, Rodriguez-Martín M, et al. Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism. J Invest Dermatol 2011; 131:2242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajawi SM, Jafarri SA, Buraik MA, et al. Pathogenesis-based therapy: Cutaneous abnormalities of CHILD syndrome successfully treated with topical simvastatin monotherapy. JAAD Case Rep 2018; 4:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu X, Zhang J, Gu Y, et al. CHILD syndrome mimicking verrucous nevus in a Chinese patient responded well to the topical therapy of compound of simvastatin and cholesterol. J Eur Acad Dermatol Venereol 2018; 32:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atzmony L, Lim YH, Hamilton C, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ugwu N, Choate KA, Atzmony L. Two percent lovastatin ointment as a pathogenesis-directed monotherapy for porokeratosis. JAAD Case Rep 2020; 6:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Happle R, Koch H, Lenz W. The CHILD syndrome. Congenital hemidysplasia with ichthyosiform erythroderma and limb defects. Eur J Pediatr 1980; 134:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil S, Bardawil T, Saade S, et al. Use of Topical Glycolic Acid Plus a Lovastatin-Cholesterol Combination Cream for the Treatment of Autosomal Recessive Congenital Ichthyoses. JAMA Dermatol 2018; 154:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol 2017; 139:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czarnowicki T, He H, Leonard A, et al. The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. J Invest Dermatol 2018; 138:2157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim M, Mikhaylov D, Sun M, et al. Ichthyosis transcriptome reveals increased atherosclerosis markers and immune and barrier differences amongst subtypes. J Invest Dermatol 2021; 141:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malik K, He H, Pavel A, et al. RNAseq profiling highlights immune and barrier differences among ichthyoses. J Invest Dermatol 2020; 140:S28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller AS. Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. J Invest Dermatol 2019; 139:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luchsinger I, Knöpfel N, Theiler M, et al. Secukinumab Therapy for Netherton Syndrome. JAMA Dermatol 2020; 156:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Volc S, Maier L, Gritsch A, et al. Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl. Br J Dermatol 2020; 183:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefferdink RL, Chima M, Ibler E, et al. Randomized, double-blind, placebo-controlled study of efficacy and safety of secukinumab to treat adults with ichthyoses. J Invest Dermatol 2021; 141:S74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller AS, Czarnowicki T, Renert-Yuval Y, et al. The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab. J Am Acad Dermatol 2018; 78:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Q, Wine Lee L, Hall EK, et al. Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes. Pediatr Dermatol 2021; 38:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frommherz LH, Schempp CM, Has C. Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol 2021; 184:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández-Martín A, Kennedy-Batalla R, Cañedo E, et al. Imbalance in T-Helper 17 Cells and Targeted Therapy in an Infant with SAM-like Syndrome. N Engl J Med 2019; 381:2176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aktas M, Salman A, Apti Sengun O, et al. Netherton syndrome: Temporary response to dupilumab. Pediatr Dermatol 2020; 37:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steuer AB, Cohen DE. Treatment of Netherton Syndrome With Dupilumab. JAMA Dermatol 2020; 156:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Süßmuth K, Traupe H, Loser K, et al. Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling. J Eur Acad Dermatol Venereol 2021; 35:e152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murase C, Takeichi T, Taki T, et al. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome. J Dermatol Sci 2021; 102:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreasen TH, Karstensen HG, Duno M, et al. Successful treatment with dupilumab of an adult with Netherton syndrome. Clin Exp Dermatol 2020; 45:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 2011; 131:1947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yalcin AD. A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol 2016; 38:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbieux C, Bonnet des Claustres M, de la Brassinne M, et al. Duality of Netherton syndrome manifestations and response to ixekizumab. J Am Acad Dermatol 2021; 84:1476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di WL, Mellerio JE, Bernadis C, et al. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum Gene Ther Clin Dev 2013; 24:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di WL, Lwin SM, Petrova A, et al. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. Hum Gene Ther 2019; 30:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abeni D, Rotunno R, Diociaiuti A, et al. A multicenter study on quality of life of the "greater patient" in congenital ichthyoses. Orphanet J Rare Dis 2021; 16:440.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128456 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23384018" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Systemic retinoids in the management of ichthyoses and related skin types.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25046443" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Ichthyosis in the Neonatal Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33169909" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33169909" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of ichthyosis–There is always something you can do! In Memoriam: Wolfgang Küster
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20398816" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Scaly skin and bath pH: rediscovering baking soda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23384017" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Topical treatment of ichthyoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595441" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Atopic dermatitis and ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3071400" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Dry skin and skin moisturizers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124857" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Active agents in common skin care products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26431582" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The distinct skin microbiota of congenital ichthyoses
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24320105" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss, and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized, double-blind, clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19134433" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22995032" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113455" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Melaleuca oil (tea tree oil) dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173437" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Tea tree oil: contact allergy and chemical composition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31062435" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Burden of itch in ichthyosis: a multicentre study in 94 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25607907" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25607907" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25607907" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355358" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effective treatment of severe thermodysregulation by oral retinoids in a patient with recessive congenital lamellar ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11858383" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Oral acitretin treatment in severe congenital ichthyosis of the neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8818186" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14705802" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Effect of the lactic acid bacterium Streptococcus thermophilus on stratum corneum ceramide levels and signs and symptoms of atopic dermatitis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23311666" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Bioactives from probiotics for dermal health: functions and benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4412623" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Control of keratinization with alpha-hydroxy acids and related compounds. I. Topical treatment of ichthyotic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3543073" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14572704" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Management of ichthyosis in infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22007909" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5067128" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Propylene glycol with occlusion for treatment of ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10606847" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4757491" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A keratolytic gel containing salicylic acid in propylene glycol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780481" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acute percutaneous lactic acid poisoning in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9099329" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Salicylate intoxication using a skin ointment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24472429" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A review of toxicity from topical salicylic acid preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29064881" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Propylene Glycol in Contact Dermatitis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3974044" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hyperosmolality induced by propylene glycol. A complication of silver sulfadiazine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3813623" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : High plasma urea concentration in babies with lamellar ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3740911" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : High plasma urea concentrations in collodion babies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30216406" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of congenital ichthyoses: European guidelines of care, part one.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33652835" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Trifarotene: A Current Review and Perspectives in Dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28730635" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lamellar ichthyosis associated bilateral pseudoainhum of fingers and toes successfully treated with tazarotene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12823301" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Type I lamellar ichthyosis improved by tazarotene 0.1% gel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16918639" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Erythrokeratoderma variabilis successfully treated with topical tazarotene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20645539" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Rapid improvement in digital ischemia and acral contracture in a collodion baby treated with topical tazarotene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28815772" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677086" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Topical tazarotene for the treatment of ectropion in ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10583110" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of topical tazarotene in the treatment of congenital ichthyoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191859" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30460372" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17373148" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215715" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27438290" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Alitretinoin: A Review in Severe Chronic Hand Eczema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2965549" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acitretin in the symptomatic therapy for severe recessive x-linked ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26381864" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Ichthyosis with confetti: clinics, molecular genetics and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12437552" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acitretin for erythrokeratodermia variabilis in a 9-year-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25546246" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Treatment of keratitis-ichthyosis- deafness (KID) syndrome in children: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29159249" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Visual impairment reversal with oral acitretin therapy in keratitis-ichthyosis-deafness (KID) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29315485" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : KLICK syndrome: an unusual phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29704247" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11558869" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6461675" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32246970" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The adverse effect profile of acitretin in a pediatric dermatology population-Longitudinal cohort study and recommendations for monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28542914" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy and adverse events of oral isotretinoin for acne: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26897386" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Guidelines of care for the management of acne vulgaris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23543097" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pseudotumor cerebri in a child treated with acitretin: a rare occurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32006604" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Ichthyosis affects mental health in adults and children: A cross-sectional study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11030769" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10584733" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Topical N-acetylcysteine for lamellar ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21793884" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Successful treatment with topical N-acetylcysteine in urea in five children with congenital lamellar ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29582451" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Topical N-acetylcysteine in ichthyosis: Experience in 18 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30152557" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Topical carbocysteine: A new option for the treatment of ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16922943" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Evidence of a marked 25-hydroxyvitamin D deficiency in patients with congenital ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18070213" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Ichthyosiform erythroderma with rickets: report of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21967076" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vitamin D deficiency and rickets in children and adolescents with ichthyosiform erythroderma in type IV and V skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26721572" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Vitamin D: A New Promising Therapy for Congenital Ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26745253" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Global Consensus Recommendations on Prevention and Management of Nutritional Rickets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15197002" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Successful treatment of Netherton's syndrome with topical calcipotriol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947208" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of topical calcipotriol on congenital ichthyoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15231983" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Nutritional rickets in ichthyosis and response to calcipotriene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21339420" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999114" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Improved Management of Harlequin Ichthyosis With Advances in Neonatal Intensive Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23384016" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Care of the newborn with ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32332691" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Ophthalmic Consequences of Ichthyosis and the Role of Systemic Retinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11231785" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Ocular management of harlequin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208260" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32543709" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Successful correction of ichthyosis-related ectropion by autografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24601965" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Frequency of ear symptoms and hearing loss in ichthyosis: a pilot survey study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21753784" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Pathogenesis-based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29687057" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Pathogenesis-based therapy: Cutaneous abnormalities of CHILD syndrome successfully treated with topical simvastatin monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29341259" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : CHILD syndrome mimicking verrucous nevus in a Chinese patient responded well to the topical therapy of compound of simvastatin and cholesterol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31449901" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33005717" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Two percent lovastatin ointment as a pathogenesis-directed monotherapy for porokeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7408908" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The CHILD syndrome. Congenital hemidysplasia with ichthyosiform erythroderma and limb defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30208477" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Use of Topical Glycolic Acid Plus a Lovastatin-Cholesterol Combination Cream for the Treatment of Autosomal Recessive Congenital Ichthyoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27554821" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29660300" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Ichthyosis transcriptome reveals increased atherosclerosis markers and immune and barrier differences amongst subtypes
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : RNAseq profiling highlights immune and barrier differences among ichthyoses
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30670307" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459284" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Secukinumab Therapy for Netherton Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31977080" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Randomized, double-blind, placebo-controlled study of efficacy and safety of secukinumab to treat adults with ichthyoses
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29066275" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33275305" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33205394" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774967" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Imbalance in T-Helper 17 Cells and Targeted Therapy in an Infant with SAM-like Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32951242" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Netherton syndrome: Temporary response to dupilumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31995125" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Treatment of Netherton Syndrome With Dupilumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32810299" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33773888" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32472705" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Successful treatment with dupilumab of an adult with Netherton syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21654837" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26592187" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32692997" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Duality of Netherton syndrome manifestations and response to ixekizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24329107" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31288584" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670609" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A multicenter study on quality of life of the "greater patient" in congenital ichthyoses.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
